Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Psoriasis/Psoriatic Arthritis Update: A Team Based Approach to Elevated Care
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Released: August 27, 2021 Expiration: August 26, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
April W. Armstrong, MD, MPH
Philip Mease, MD, MACR

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply guideline recommendations for psoriasis and PsA treatment selection according to disease severity, treatment history, and functional and QoL status
  • Describe common comorbidities associated with psoriatic disease and strategies for identifying and managing these conditions
  • Outline coordination of care with other healthcare professionals that fosters a whole-patient approach to psoriatic disease and related conditions and concerns

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

April W. Armstrong, MD, MPH

Professor of Dermatology and Associate Dean
Department of Dermatology
Keck School of Medicine of USC
Associate Dean for Clinical Research
Department of Dermatology
Director
Clinical Research Support, Southern California Clinical and Translational Science Institute (SC CTSI)
Vice Chair
Director,
Clinical Trials and Outcomes Research
Director, Psoriasis Program
Los Angeles, California

April W. Armstrong, MD, MPH, has disclosed that she has received consulting fees from AbbVie, Aslan, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavent, Dermira, EPI Health, Incyte, Janssen, Leo, Lilly, Novartis, Ortho, Parexel, Pfizer, Regeneron, Sanofi, Sun, and UCB and funds for research support from Bristol-Myers Squibb, Dermavent, Dermira, Lilly, Leo, Pfizer, and UCB.
Philip Mease, MD, MACR

Clinical Professor
School of Medicine
University of Washington
Director
Rheumatology Research
Swedish Medical Center
Providence St Joseph Health
Seattle, Washington

Philip Mease, MD, MACR, has disclosed that he has received consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; funds for research from AbbVie, Amgen, Bristol-Myers Squibb, Galapagos, Gilead Sciences, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and fees for non-CME/CE services from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB.

Staff

Craig Borders
Vice President, Managing Scientific Director
Craig Borders has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Jennifer Simpson, DNP
Jennifer Simpson, DNP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for rheumatologists, dermatologists, primary care physicians, nurse practitioners, and other healthcare professionals who care for patients with psoriatic disease.

Goal

The goal of this activity is to improve learners’ knowledge and competence in applying current and emerging treatment strategies in the holistic management of patients with psoriasis and PsA.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 27, 2021, through August 26, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Psoriasis/Psoriatic Arthritis Update: A Team Based Approach to Elevated Care
  • CME
  • CE

Loading...
In this interactive on-demand Webcast, expert faculty discuss best practices and emerging strategies in the holistic management of patients with psoriasis and PsA.
April W. Armstrong, MD, MPH
Philip Mease, MD, MACR
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Released: August 27, 2021 Expiration: August 26, 2022

Related Content

From Clinical Care Options (CCO), new data in managing axial psoriatic arthritis and axial spondyloarthritis from EULAR 2021

Atul Deodhar, MD Philip Mease, MD, MACR Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: September 2, 2021 Expired: September 1, 2022

Clinical Care Options (CCO) faculty Dr. April Armstrong and Dr. Philip Mease discuss problem of access to dermatologists and rheumatologists experienced by patients with PsO and PsA and potential solutions

April W. Armstrong, MD, MPH Philip Mease, MD, MACR Released: August 20, 2021

Dr Philip Mease discusses key studies from EULAR 2021 on axSpA and axPsA that will affect clinical practice, reported by Clinical Care Options (CCO)

Philip Mease, MD, MACR Released: August 10, 2021

From EULAR 2021 and Clinical Care Options (CCO), new data on MRI scoring of structural lesions in sacroiliac joints in axSpA

Released: August 3, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue